Brokerages Set Century Therapeutics, Inc. (NASDAQ:IPSC) PT at $10.00

Century Therapeutics, Inc. (NASDAQ:IPSC - Get Free Report) has received an average recommendation of "Buy" from the six brokerages that are covering the stock, MarketBeat reports. Six research analysts have rated the stock with a buy recommendation. The average 1-year target price among brokers that have covered the stock in the last year is $10.00.

A number of equities analysts have recently weighed in on IPSC shares. Piper Sandler dropped their target price on Century Therapeutics from $12.00 to $4.00 and set an "overweight" rating on the stock in a report on Monday, December 30th. HC Wainwright reiterated a "buy" rating and issued a $5.00 price objective on shares of Century Therapeutics in a research note on Wednesday, January 22nd. Finally, Guggenheim reissued a "buy" rating on shares of Century Therapeutics in a research note on Wednesday, January 22nd.

Institutional Trading of Century Therapeutics

Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its holdings in shares of Century Therapeutics by 3.5% during the 3rd quarter. Geode Capital Management LLC now owns 968,182 shares of the company's stock valued at $1,656,000 after purchasing an additional 32,614 shares in the last quarter. Barclays PLC raised its holdings in Century Therapeutics by 283.6% during the third quarter. Barclays PLC now owns 61,945 shares of the company's stock valued at $106,000 after buying an additional 45,797 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of Century Therapeutics by 257.6% in the third quarter. JPMorgan Chase & Co. now owns 71,721 shares of the company's stock worth $123,000 after buying an additional 51,664 shares during the last quarter. State Street Corp boosted its stake in shares of Century Therapeutics by 7.4% during the 3rd quarter. State Street Corp now owns 836,914 shares of the company's stock worth $1,431,000 after acquiring an additional 57,323 shares in the last quarter. Finally, Wellington Management Group LLP acquired a new position in shares of Century Therapeutics during the 3rd quarter valued at about $284,000. 50.20% of the stock is owned by institutional investors.

Remove Ads

Century Therapeutics Stock Performance

Shares of IPSC stock traded down $0.04 on Thursday, reaching $0.56. 587,387 shares of the company's stock traded hands, compared to its average volume of 364,372. The company has a market capitalization of $47.49 million, a P/E ratio of -0.30 and a beta of 1.75. Century Therapeutics has a 12-month low of $0.55 and a 12-month high of $5.24. The business's 50 day moving average price is $0.80 and its two-hundred day moving average price is $1.21.

Century Therapeutics Company Profile

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.